1. Home
  2. FBRT vs OMER Comparison

FBRT vs OMER Comparison

Compare FBRT & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin BSP Realty Trust Inc.

FBRT

Franklin BSP Realty Trust Inc.

HOLD

Current Price

$9.04

Market Cap

701.9M

Sector

Real Estate

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$14.30

Market Cap

772.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBRT
OMER
Founded
2012
1994
Country
United States
United States
Employees
223
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
701.9M
772.8M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
FBRT
OMER
Price
$9.04
$14.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$11.50
$32.50
AVG Volume (30 Days)
587.9K
1.0M
Earning Date
04-29-2026
05-14-2026
Dividend Yield
15.83%
N/A
EPS Growth
N/A
98.15
EPS
N/A
N/A
Revenue
N/A
$29,868,000.00
Revenue This Year
$12.34
N/A
Revenue Next Year
$4.95
$233.22
P/E Ratio
$13.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.24
$2.95
52 Week High
$11.84
$17.65

Technical Indicators

Market Signals
Indicator
FBRT
OMER
Relative Strength Index (RSI) 51.56 60.96
Support Level $8.91 $10.82
Resistance Level $9.26 $15.32
Average True Range (ATR) 0.19 0.61
MACD -0.00 -0.02
Stochastic Oscillator 24.58 56.71

Price Performance

Historical Comparison
FBRT
OMER

About FBRT Franklin BSP Realty Trust Inc.

Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. The Company's operations are organized into two business units: (i) Commercial Real Estate Financing, and (ii) Agency Business. Its four reporting segments are as follows: The real estate debt business, The Agency Business, The commercial real estate conduit business, and The real estate owned business.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: